Royalty Report: Drugs, Therapeutic, Vaccine – Collection: 282940

$100.00

Curated Royalty Rate Report
Category: Technology Licenses, Created On: 2022-04-28, Record Count: 3

Description

This collection of transactions and supporting information was developed using our AI algorithm to curate similar royalty reports into a cohesive collection to support your licensing, transfer pricing or other transaction scenarios where documented royalty rates and/or deal terms are important.
Category: Technology Licenses
Created On: 2022-04-28
Record Count: 3

Primary Industries

  • Drugs
  • Therapeutic
  • Vaccine

IPSCIO Report Record List

Below you will find the records curated into this collection.  This summary includes the complete licensed property description so that you can review and determine if this collection covers the topics, technology or transaction type that is relevant for your needs.  The full report will include all relevant deal data such as the royalty base, agreement date, term description, royalty rates and other deal terms.  For reference, here is a sample of a full IPSCIO curated royalty rate report: Sample Report

IPSCIO Record ID: 282940

License Grant
The parties agree to amend the agreements into the master amendment to clarify the understanding and intent of the Agreements relating to the U. S. Agreement regarding the development, manufacture (to the extent set forth in the Supply Agreement), distribution, use, marketing and co-promotion of Licensor’s proprietary intranasally delivered cold-adapted vaccine formulation against influenza and influenza-associated illnesses, including otitis media infection, known as FluMist™ or FluEnz™ (collectively, “FluMist”), in the United States and its territories and possessions; the International Agreement that exclusively develop, manufacture (to the extent set forth in the Supply Agreement), distribute, use, market and sell FluMist in certain territories outside of the United States and its territories and possessions and the Supply Agreement that provides for the manufacture and supply of the Frozen Product and the Liquid Product (as such terms are defined in the Supply Agreement) for distribution and sale by Licensee under the terms and conditions of the U.S. Agreement and International Agreement.
License Property
FluMistâ„¢ or FluEnzâ„¢ is a proprietary intranasally delivered cold-adapted vaccine formulation against influenza and influenza-associated illnesses, including otitis media infection.

Frozen and/or Liquid Product relating to the formulation of the product.

Field of Use
This agreement pertains to the drug industry.

IPSCIO Record ID: 227248

License Grant
Licensor grants the exclusive license, under the Licensor Patents, the Licensor Know-How and Licensors interest in any Joint Technology; and the exclusive sublicense under Licensor s rights under the the Materials Transfer and Intellectual Property Agreement, in each case solely to manufacture, to the extent set forth in the Supply Agreement, develop, distribute, use. import, offer for sale and sell the Product in the Territory for use in the Field during the term of the Agreement.

Licensor grants the right to grant a sublicense, under its exclusive license granted, to Medeva Pharma PLC, to use, market, sell, and distribute the Product for use in the Field, solely in the United Kingdom.

Licensor grants a non-assignable, sublicenseable, exclusive right and license to use Licensors Trademarks, as applicable, in the Territory solely in connection with the Product Promotional Materials and Product Labeling during the term of the Agreement.

License Property
Licensor has an intranasally delivered cold adapted vaccine formulation against influenza and influenza-associated illnesses, including otitis media infection, known as FluMist(TM).  The Primary Brand Trademark means FluMistâ„¢ and FluEnzâ„¢, as well as any brand names combining FluMist or FluEnz with other words, e.g. Pediatric FluMist.

The product means Licensors live, attenuated, intranasally delivered, cold adapted influenza vaccine derived from the Master Donor Strains, including, but not limited to, the Frozen Formulation and the Liquid Formulation; provided, however, that Product specifically excludes any other Formulation or mode of delivery other than intranasal spray unless and until such Other Formulation or mode of delivery has been included under the Collaboration.  Product also specifically excludes any influenza vaccine Controlled by Licensor which is solely based upon or derived from strains other than the Master Donor Strains and their derivatives or other technologies of Licensor;  any product comprising Licensors live, attenuated, intranasally delivered, cold adapted influenza vaccine derived from the Master Donor Strains in combination with any other vaccine or vaccines; and, any product in which a viral vector derived from the Master Donor Strains is used to deliver a vaccine or other heterologous gene sequence for use in the prevention, mitigation or cure of influenza.

Field of Use
The Field means the use of the Product pursuant to a physicians direct or standing prescription to prevent influenza and influenza-associated illnesses including otitis media infection in a Target Population. or other population, for which the Product, as to a regulatory jurisdiction, has been granted Regulatory Approval by the Relevant Agency; or, for any, other Indications which are specifically included under the Collaboration.  The Field specifically excludes use or sale of the Product in the OTC Market.

IPSCIO Record ID: 230760

License Grant
Licensor grants the exclusive license, under the Licensor Patents, the Licensor Know-How and Licensors interest in any Joint Technology; and,  the exclusive sublicense, under Licensors rights under a Materials Transfer and Intellectual Property Agreement, in each case solely to manufacture, to the extent set forth in the Supply Agreement, develop, distribute, use, import, offer for sale and sell the Product in the Territory for use in the Field during the Co-Promotion Term.

Licensor grants the right to distribute Product through its Affiliates or Third Party distributors in the Territory, but in any event only through distributors performing usual and customary distribution activities for Licensee, to the extent that Licensee itself otherwise has the right to so distribute such Product in the Territory for use in the Field during the Co-Promotion Term, provided that Licensee may not grant any such distributor a sublicense hereunder to offer for sale or sell, or repackage, re-import or export the Product.

License Property
Licensor has an intranasally delivered cold adapted vaccine formulation against influenza and influenza-associated illnesses, including otitis media infection, known as FluMist(TM).  The primary brand trademark means FluMist(TM) and FluEnz(TM), as well as any brand names combining FluMist or FluEnz with other words, e.g. Pediatric FluMist.

The product means Licensors live, attenuated, intranasally delivered, cold adapted influenza vaccine derived from the Master Donor Strains, including, but not limited to, the Frozen Formulation and the Liquid Formulation; provided, however, that Product specifically excludes any other Formulation or mode of delivery other than intranasal spray unless and until such Other Formulation or mode of delivery has been included under the Collaboration.  Product also specifically excludes any influenza vaccine Controlled by Licensor which is solely based upon or derived from strains other than the Master Donor Strains and their derivatives or other technologies of Licensor;  any product comprising Licensors live, attenuated, intranasally delivered, cold adapted influenza vaccine derived from the Master Donor Strains in combination with any other vaccine or vaccines; and, any product in which a viral vector derived from the Master Donor Strains is used to deliver a vaccine or other heterologous gene sequence for use in the prevention, mitigation or cure of influenza.

Field of Use
Field means the use of the Product pursuant to a physicians direct or standing prescription to prevent influenza and influenza-associated illnesses including otitis media infection in a Target Population, or other population, for which the Product is approved by the FDA; or, for any other indication which are specifically included under the Collaboration.  The Field specifically excludes use or sale of the Product in the OTC Market.
Disclaimer: The information gathered from RoyaltySource® database was sourced from the U.S. Securities and Exchange Commission EDGAR Filings and other public records. While we believe the sources to be reliable, this does not guarantee the accuracy or completeness of the information provided. Further, the information is supplied as general guidance and is not intended to represent or be a substitute for a detailed analysis or professional judgment. This information is for private use only and may not be resold or reproduced without permission.